Comparison · NCT00077636-sae
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks vs PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks vs PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks: serious adverse events. Trial comparisons, record NCT00077636-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00077636-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0465 | 0.0335 | 0.0643 | wilson | |
| Risk in group 2 | 0.0646 | 0.0489 | 0.0848 | wilson | |
| Risk difference, group 1 minus group 2 | -0.018 | -0.0421 | 0.00565 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.72 | 0.469 | 1.11 | log | |
| Odds ratio, group 1 over group 2 | 0.707 | 0.449 | 1.11 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks than on PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks | 55.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks | Participants were administered 180 micrograms (μg) of PEG-IFN alfa-2a once weekly and 800 milligrams (mg) of ribavirin daily for 16 weeks. | 34 | 731 | EG000 |
| Group 2 | PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks | Participants were administered 180 μg of PEG-IFN alfa-2a once weekly and 800 mg of ribavirin daily for 24 weeks. | 47 | 728 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to week 48
Source ClinicalTrials.gov
Trial
- Title
- ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
- NCT number
- NCT00077636
- Phases
- PHASE4
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Copegus, peginterferon alfa-2a [Pegasys], peginterferon alfa-2a [Pegasys]
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2016-01-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00077636?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00077636-sae